论文部分内容阅读
目的:卵巢癌是女性生殖器官常见的恶性肿瘤,肿瘤干细胞理论认为卵巢癌中存在肿瘤干细胞,并且肿瘤干细胞是肿瘤复发、转移、耐药的罪魁祸首。Oct4是细胞干细胞特性的重要标志之一。本文旨在探讨Oct4蛋白在晚期浆液性卵巢癌的表达情况,并分析其表达水平与患者临床病理特征之间的关系。方法:采用免疫组化法检测101例晚期浆液性卵巢癌中Oct4蛋白的表达情况,并结合临床资料分析Oct4蛋白的表达水平在晚期浆液性卵巢癌患者中的意义。结果:晚期浆液性卵巢癌患者中Oct4阳性表达率为87.1%(88/101),其表达水平和患者的年龄、病理分化程度、淋巴结转移情况及临床分期无明显相关性(P>0.05),但是其高表达与化疗耐药明显相关(P=0.023)。结论:我们的研究证明Oct4在晚期浆液性卵巢癌中有较高表达,并且Oct4的表达与卵巢癌化疗后复发有关;理论上支持在晚期浆液性卵巢癌中可能存在肿瘤干细胞,且比例较高,肿瘤干细胞的比率和卵巢癌化疗耐药相关。Oct4可能是晚期浆液性卵巢癌治疗的新靶点。
OBJECTIVE: Ovarian cancer is a common malignant tumor of female genital organs. Cancer stem cell theory holds that tumor stem cells exist in ovarian cancer, and cancer stem cells are the main culprit of tumor recurrence, metastasis and drug resistance. Oct4 is one of the important hallmarks of the characteristics of cell stem cells. This article aims to investigate the expression of Oct4 protein in advanced serous ovarian cancer and to analyze the relationship between its expression level and the clinicopathological features of patients. Methods: The expression of Oct4 protein in 101 patients with advanced serous ovarian cancer was detected by immunohistochemistry. The significance of Oct4 protein expression in patients with advanced serous ovarian cancer was analyzed based on clinical data. Results: The positive expression rate of Oct4 in patients with advanced serous ovarian cancer was 87.1% (88/101). There was no significant correlation between the expression of Oct4 and age, pathological differentiation, lymph node metastasis and clinical stage (P> 0.05) However, its high expression was significantly associated with chemoresistance (P = 0.023). Conclusions: Our study demonstrated that Oct4 is highly expressed in advanced serous ovarian cancer, and Oct4 expression is associated with relapse after chemotherapy in ovarian cancer; in theory, it is possible to support the possible presence of tumor stem cells in advanced serous ovarian cancer with a higher proportion , The ratio of cancer stem cells and ovarian cancer chemotherapy-resistant. Oct4 may be a new target for the treatment of advanced serous ovarian cancer.